| Old Articles: <Older 2001-2010 Newer> |
|---|
 |
The Motley Fool
May 13, 2005
Seth Jayson |
With PainCare, Beware With PainCare Holding's growth fueled by acquisitions that are in turn fueled by borrowing and inflating stock price, which is in turn fueled by hype, I'm not sure this is a good stock for anyone, especially if that cycle breaks.   |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
May 9, 2005
Stephen D. Simpson |
Integra LifeSciences Strikes a Nerve The med-tech company's missed quarter coupled with some slightly disappointing guidance caused investors to lose a bit of faith, sending the shares down more than 15% at one point. |
BusinessWeek
May 16, 2005
Kerry Capell |
Britain: From Swamp Fox To Healer Renovo's CEO turned a chance find into a promising anti-scarring treatment. An IPO of Renovo's shares on the London Stock Exchange later this month aims to raise $124 million, making it the biggest biotech IPO in Europe in several years. |
BusinessWeek
May 16, 2005
Arlene Weintraub |
Bristling With Promise Start-up Curis is developing a class of drugs that could halt hair loss -- and treat cancer |
The Motley Fool
May 6, 2005
Stephen D. Simpson |
Psychiatric Solutions Thinks Bigger A major acquisition will mean more debt, but more growth as well. |
The Motley Fool
May 5, 2005
Stephen D. Simpson |
Will Anybody Love Angiotech? Despite the success of the Boston Scientific Taxus stent, Angiotech's stock is trading at low levels. |
The Motley Fool
May 5, 2005
Charly Travers |
OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech. |
The Motley Fool
May 5, 2005
Brian Gorman |
Boning Up at Genzyme In its latest acquisition, the biotech claims a line of products from Bone Care. But is the company spreading itself a little too thin? |
| <Older 2001-2010 Newer> Return to current articles. |
